

May 29, 2014



Xenetic Biosciences to Present at the Third Annual Marcum MicroCap Conference

LEXINGTON, Mass., May 29, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announced today that the Company will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel.

The Company's presentation by Scott Maguire, CEO of Xenetic, is scheduled to begin at 11:30 a.m. EDT and will be available via a live webcast. To access the webcast, go to <http://ir.xeneticbio.com/> or <http://wsj.com/webcast/marcum2/xbio/>.

The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than \$500 million in market capitalization. For more information or to register, please visit the conference website at <http://www.marcumllp.com/microcap/>.

About Xenetic Biosciences

Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for creating next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs and OncoHist™ for the development of novel oncology drugs focused on orphan indications. Xenetic's lead product candidates include ErepoXen®, an improved, polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease and OncoHist™, a recombinant human histone H1.3 molecule which Xenetic is developing for the treatment of refractory Acute Myeloid Leukemia (AML). Xenetic is developing a novel series of polysialylated blood coagulation factors through its license agreement with Baxter International Inc. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company's website at www.xeneticbio.com.

CONTACT: Xenetic Contacts:

Xenetic Biosciences, Inc.
M. Scott Maguire, Chief Executive Officer
781 778 7720
j.mccusker@xeneticbio.com

U.S. Contact:
Stern Investor Relations

Paul Cox
212 362 1200
paul@sternir.com

UK/European Contact:
Walbrook PR
Mike Wort
+44 (0)20 7933 8780
mike.wort@walbrookpr.com

Source: Xenetic Biosciences, Inc.